-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

614.O1.6 614. Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies: Clinical Trials

Symposia: Acute Lymphoblastic Leukemias: Therapies, Excluding Transplantation and Cellular Immunotherapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, clinical trials, Lymphoid Leukemias, ALL, Biological therapies, Antibody Therapy, adult, Translational Research, Non-Biological therapies, Bispecific Antibody Therapy, elderly, Clinical Research, Chemotherapy, Combination therapy, Diseases, Therapies, Adverse Events, Lymphoid Malignancies, Study Population, Human, Minimal Residual Disease
Saturday, December 10, 2022: 2:00 PM-3:30 PM
265-268 (Ernest N. Morial Convention Center)
Moderators:
Emily K Curran, MD, University of Cincinnati Cancer Center and Shella Saint Fleur-Lominy, MD, PhD, New York University Grossman School of Medicine
Disclosures:
Curran: Amgen: Consultancy, Other: Participation in advisory board; Incyte: Consultancy, Other: Participation in advisory board; Kite: Consultancy, Other: Participation in advisory board; Pfizer: Consultancy, Other: Participation in advisory board; Tempus: Consultancy, Other: Participation in advisory board; Servier: Consultancy, Honoraria, Other: Participation in advisory board; participation in expert panel guidelines.
The session includes abstracts for both pediatric and adult patients with ALL from early phase to randomized phase III therapeutic trials, excluding transplant and cellular therapies.
2:00 PM

Nicolas Boissel, MD, PhD1,2, Francoise Huguet, MD3*, Thibaut Leguay, MD4*, Mathilde Hunault, MD; PhD5*, Rathana KIM, PharmD6*, Yosr Hicheri, MD7*, Patrice Chevallier, MD8, Marie Balsat9*, Sébastien Maury10*, Anne Thiebaut-Bertrand11*, Florence Van Obbergh12*, Thomas Cluzeau, MD, PhD13, Martine Escoffre-Barbe, MD14*, Nicole Straetmans, MD, PhD15, Johanna Konopacki16*, Amine Belhabri17*, Alban Villate, MD18*, Florence Pasquier, MD, PhD19*, Ioana Vaida, MD20*, Laurence Sanhes, MD21*, Magda Alexis, MD22*, Cedric Pastoret, MD, PhD23*, Mathlide Lamarque, MD24*, Laure Farnault, MD25*, Nathalie Grardel, MD26*, Celine Berthon, MD, PhD27*, Eric Delabesse, MD, PhD28*, Veronique Lheritier29*, Norbert Ifrah, MD PhD30, Carlos Graux31*, Yves Chalandon, MD32, Emmanuelle Clappier, PharmD, PhD33* and Herve Dombret, MD PhD34,35

1St-Louis Hospital, APHP, Adolescent and Young Adult Hematology Department, Paris, France
2URP-3518, Saint-Louis Research Insitute, Université Paris Cité, Paris, France
3Department of Hematology, Institut Universitaire du Cancer-Oncopole CHU de Toulouse, Toulouse, France
4Hematology Clinic, Bordeaux University Hospital, Pessac, France
5Clinical Hematology, CHU d'Angers, Angers, France
6Hematology laboratory, Assistance Publique Des Hopitaux De Paris (AP-HP) - Universite Paris Descartes -, Paris, Ile-de-France, France
7Departement d'Hematologie, Institut Paoli-Calmettes, MARSEILLE, France
8Hematology Department, Nantes University Hospital, Nantes, France
9Service Hematologie, Centre Hospitalier Lyon Sud, Lyon, France
10Service d’Hématologie clinique, Hôpitaux universitaires Henri-Mondor (AP-HP), Créteil, FRA
11CHU de Grenoble, Grenoble, France
12CH Jolimont, Hematology Department, La Louviere, BEL
13Département d'Hématologie Clinique, Université Côte d'Azur, CHU Nice, Nice, Provence Alpes Cote d'Azur, France
14Hôpital de Pontchaillou, Centre Hospitalier Universitaire de Rennes, Rennes, France
15Department of Hematology, Cliniques Universitaires Saint-Luc,, Woluwe Saint Lambert, BEL
16HIA PERCY, CLAMART, FRA
17Centre Leon Berard, Departement Oncologie Medicale, Lyon, France
18Service d'hématologie et thérapie cellulaire, Hôpital Bretonneau, CHRU de Tours, Tours, France
19Gustave Roussy, Département clinique d'hématologie, INSERM UMR1170, Villejuif, FRA
20Hematology Department, Pontoise Hospital, Pontoise, France
21Department of Hematology, CH de Perpignan, Perpignan, France
22CHR d'Orléans, Orleans, FRA
23INSERM U1236 /Hematology Laboratory, University Hospital of Rennes, RENNES, FRA
24Service d'Hématologie, Centre Hospitalier de Mulhouse, Mulhouse, FRA
25Service d'hématologie clinique et de thérapie cellulaire, Assistance Publique des Hôpitaux de Marseille, Centre Hospitalier Universitaire La Conception, Marseille, France
26Laboratory of Hematology, Centre Hospitalier Universitaire Lille, Lille, France
27Hematology Department, Lille University Hospital, Lille, France
28Hematology Laboratory, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
29Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL), Centre Hospitalier Lyon Sud, Lyon, France
30Clinical Hematology, Angers University Hospital, Angers, France
31Université Catholique de Louvain, CHU UCL Namur (Godinne), Yvoir, Belgium
32Geneva University Hospitals, Geneva, Switzerland
33Hematology Laboratory and INSERM U944, Saint-Louis Hospital, AP-HP, Paris, France
34URP-3518, Institut de Recherche Saint-Louis, Université Paris Cité, Paris, France
35Hopital Saint-Louis, Assistance Publique - Hopitaux De Paris (AP-HP), Paris, FRA

2:15 PM

Matthias Stelljes, Prof. Dr. med.1, Nael Alakel, MD2*, Ralph Wäsch3, Sebastian Scholl, MD4*, Kathrin Nachtkamp, MD5*, Andreas Rank, MD6*, Mathias Haenel, MD7*, Bernd Spriewald, MD8*, Maher Hanoun, MD, PhD9*, Sonja Martin, MD10*, Katjana Schwab, MD11*, Julian Knaden12*, Lena Reiser13*, Julia Marx, MD14*, Klaus Wethmar, MD15*, Tim Sauer, MD16*, Wolfgang E. Berdel, MD17, Georg Lenz, MD, Prof.18, Monika Brüggemann19*, Simon Raffel, MD20 and Nicola Goekbuget, MD13

1Department of Medicine / Hematology and Oncology, University of Muenster, Muenster, Germany
2University Hospital TU Dresden, Germany, Dresden, Germany
3Department of Hematology, Oncology and Stem Cell Transplantation, University Medical Center Freiburg, Freiburg, Germany
4University Hospital Jena, Jena, Germany
5Department of Hematology, Oncology and Clinical Immunology, Universitätsklinik Düsseldorf, Düsseldorf, Germany
6Medical Clinic II, University Hospital of Augsburg, Augsburg, Germany
7Klinikum Chemnitz, Chemnitz, Germany
8Med. Klinik 5 / Hämatologie u. Internist. Onkologie, Universität Erlangen-Nürnberg, Erlangen, Germany
9Department of Hematology and Stem Cell Transplantation, University Hospital Essen, Essen, Germany
10Department of Hematology and Oncology, Robert-Bosch-Hospital, Stuttgart, Germany
11University of Bonn, Bonn, Germany
12University of Frankfurt, Frankfurt, Germany
13Department of Medicine II, Hematology/Oncology, Goethe University Hospital, Frankfurt, Germany
14Department of Hematology, Oncolog and Pneumology, University of Münster, Münster, DEU
15Department of Medicine, Hematology and Oncology, University Hospital Muenster, Muenster, Germany
16Department of Internal Medicine V, Heidelberg University Hospital, Heidelberg, Germany
17Department of Medicine A, Hematology and Oncology, University Hospital Muenster, Muenster, Germany
18Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Muenster, Muenster, Germany
19Department of Medicine II, University Hospital of Schleswig-Holstein, Kiel, Germany
20German Cancer Reseach Center, Heidelberg, Germany

2:30 PM

Nicholas Short, MD1, Hagop Kantarjian, MD2, Nitin Jain, MD3, Xuelin Huang, PhD4*, Guillermo Montalban-Bravo, MD5, Tapan M. Kadia, MD3, Naval Daver, MD5, Kelly S. Chien, MD5, Yesid Alvarado, MD5, Guillermo Garcia-Manero, MD6, Ghayas C. Issa, MD5, Walid Macaron, MD, MSc5*, Fadi Haddad, MD5*, Monica Kwari, BSN5, Ricardo Delumpa, BSN5*, Ejiroghene Mayor, BSN, RN5*, Wuliamatu Deen, BSN, RN5*, Jennifer Thankachan5*, Christopher Loiselle, BS5*, Juan Rivera5*, Anna Milton5*, Lourdes Waller5*, Glenda Banks5*, Rebecca Garris5*, Marina Konopleva, MD, PhD1, Farhad Ravandi, MD5 and Elias Jabbour, MD5

1Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
2Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Leukemia, MD Anderson Cancer Center, Houston, TX
4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX
5Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX

2:45 PM

Amy A. Kirkwood, MSc1*, Nicholas Goulden, MD, PhD, MRCPath2*, John Moppett, PhD FRCPath3*, Sujith Samarasinghe, PhD, FRCPath4*, Jon Mee5*, Rachael Hough, MD FRCPath6*, Pamela R. Kearns, PhD, FRCPC7*, Sarah Lawson, MBBS FRCPath8*, Clare J. Rowntree, MBBS PhD9* and Ajay Vora, MD10

1Cancer Research UK & UCL Cancer Trials Centre, University College London, London, United Kingdom
2Great Ormond Street Hospital, London, United Kingdom
3Department of Haematology, Bristol Children's Hospital, Bristol, United Kingdom
4Department of Paediatric Haematology, Great Ormond Street Hospital for Children, London, United Kingdom
5Cancer Clinical Trials Unit, Birmingham University, Birmingham, United Kingdom
6University College Hospital, University College of London, London, United Kingdom
7Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Birmingham, United Kingdom
8Birmingham Children's Hospital, Birmingham, United Kingdom
9Department of Haematology, University Hospital of Wales, Cardiff, United Kingdom
10Department of Haematology, Great Ormond Street Hospital for Children, London, United Kingdom

3:00 PM

Rob Pieters, Prof. MD. PhD1,2, Hester A. De Groot-Kruseman, PhD3,4*, Femke Verwer3,4*, Merian van Overveld2*, Edwin Sonneveld5,6*, Marta Fiocco, Prof. PhD2,5,7,8*, Vincent H.J. van der Velden, PhD9*, Berna Beverloo, PhD10*, Marc Bierings, MD, PhD2,5, Valerie De Haas, MD1,2*, Peter M. Hoogerbrugge, MD, PhD1,2, Inge M. Van Der Sluis, MD, PhD1,2, Wim J.E. Tissing, MD, PhD2*, Margreet Veening2*, Judith M. Boer, PhD2 and Monique L. den Boer, PhD2

1Dutch Childhood Oncology Group, Utrecht, Netherlands
2Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
3Pediatric Oncology, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
4Dutch Childhood Oncology Group (DCOG), Utrecht, Netherlands
5Dutch Childhood Oncology Group, Netherlands, Utrecht, Netherlands
6Princess MáXima Center For Pediatric Oncology, Utrecht, Netherlands
7Medical Statistics Section, Department of Biomedical Data Science, Leiden University Medical Center, Leiden, Netherlands
8Mathematical Institute, Leiden University, Leiden, Netherlands
9Department of Immunology, Erasmus University Medical Center, Rotterdam, Netherlands
10Department of Clinical Genetics, Erasmus Medical Center, Rotterdam, Netherlands

3:15 PM

Nitin Jain, MD1, Elias Jabbour, MD1, Ibrahim Aldoss, MD2, Marina Konopleva, MD, PhD1, Nicholas Short, MD3, Anthony S. Stein, MD2*, Naveen Pemmaraju, MD1, Philip A. Thompson, MBBS1, Farhad Ravandi, MD1 and Hagop Kantarjian, MD4

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Hematology and Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA
3Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
4Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

*signifies non-member of ASH